Connect with us

Market

Biotechnology Stocks That Should Be On Your List In 2016; Vycor Medical (OTCMKTS:VYCO), Northwest Biotherapeutics, Inc (NASDAQ:NWBO), HealthSouth Corp (NYSE:HLS),Pfizer (NYSE: PFE)

Published

on

Biotechnology stocks have commanded some of the most attention during the better part of 2015 and with 2016 right in front of us, the sentiment in the market remains the same. Venture capital continues to pour into the space with companies like Merck Research Lab Ventures, OrbiMed, Polaris Partners, GV, and Mission Bay Capital all putting money into new biotech endeavors. Most recently Alector LLC raised $29.5 million in a Series D financing led by the Dementia Discovery Fund. Alector LLC is a private biotech company pioneering the discovery and development of first-in-class, immuno-modulatory therapies for Alzheimer’s disease and other neurodegenerative disorders.

The focus on what they do is not necessarily the main point here; it’s the fact that millions are pouring into biotechnology right now and 2016 could be poised to see another increase in venture capital spending. This industry is already coming off of a banner 2015, where the health-care industry defied belief with $605 billion spent in M&A and other venture funding. For example, Pfizer (NYSE: PFE) last year agreed to buy Allergan Plc, a gargantuan merger partner, for $160 billion.

And it hasn’t been just for medical drug manufacturers either. In a recent announcement, health care investment firm OrbiMed Advisors LLC said that it has raised $950 million for a new venture capital fund that will focus on biopharmaceuticals, medical devices, diagnostics and health care technology companies. Their fund, OrbiMed Private Investments VI LP, was subscribed to by medical research institutions, endowments, foundations and sovereign wealth funds. It will be used to make investments in about 30 portfolio companies, with contributions ranging from $10 million to $75 million, according to a statement announcing the fundraising effort.

Let’s not forget, too, the blistering IPO arena in biotechnology. Last year started off at a robust pace, as 53 companies in biotechnology, pharmaceuticals and health-care products and services priced a total $4.27 billion worth of public offerings in the first half of the year.

This isn’t an unfamiliar territory to long-time biotech investors but may be of much more interest to new stock market participants just beginning to realize the massive opportunity that biotechnology offers as far as investment potential. But that’s thinking in today’s dollars. Just a few years ago these types of raises were limited to capitalizing very unique and game changing opportunities within the space. In fact companies like Johnson and Johnson as well as Oakwood Medical Investors, Tullis-Dickerson & Co., Inc., and several other large investment funds, participated in many funding series that totaled more than $50 million in order to capitalize a company called NovaVision for its NovaVision VRT(TM) Vision Restoration Therapy. This was and is the first and only FDA-cleared, patented, non-invasive medical device that may restore vision in stroke and traumatic brain injury patients with visual deficits.

Vycor Medical (OTCMKTS:VYCO), through an incredible purchase agreement completed at a price of $900,000, NovaVision was scooped up and its assets were merged into Vycor. Mind you, this therapy was funded with more than $50million and is the first and only therapy of its kind on the market, now owned by VYCO. As opposed to other biotech and biotherapeutic companies such as Pfizer, Northwest Biotherapeutics, Inc (NASDAQ:NWBO), or even Merck & Co., Inc. (NYSE:MRK), Vycor trades at a fraction of the price and has been able to commercialize the assets that it has in its portfolio, including NovaVision’s VRT and NeuroEyeCoach Therapy.

The market alone for NovaVision’s therapies is roughly $4bn in the US/Europe and $13bn globally. There are approximately 8m stroke survivors in the U.S. with 795,000 strokes a year, and approximately 1.5m suffering some sort of Traumatic Brain Injury (TBI) annually; around 2.8 million Americans suffer from this type of vision impairment, which is largely unaddressed by the rehabilitation system. VRT on its own is supported by 15 years of clinical research and over 20 studies including a 302 patient study in which notable improvements were seen in 70% of the patients. NeuroEyeCoach is also clinically supported being based on research that has been the subject of 14 clinical studies on a total of 591 patients and has FDA registration.

As of the most recent quarterly report, VYCO reported a gross margin of nearly 90% for the 3rd quarter 2015 with 22% of that coming from NovaVision. In addition, the agreement with HealthSouth Corp (NYSE:HLS), the company has put these therapies in the hands of one of the largest providers of post-acute healthcare services in the U.S. These two agreements therefore provide NovaVision with a source of installation and rental income but equally as important is a potentially large source of patients; most stroke patients will touch a rehabilitation center at some point and HealthSouth is the largest network of stroke rehabilitation hospitals in the U.S.

Continue Reading

Biotech

CytoDyn Inc (OTCMKTS:CYDY) Regains Momentum After The Big Announcement

Published

on

By

Now that the market seems to be coming back into his elements, it could be time for investors to start looking into penny stocks more closely. These stocks may often be risky, but if one makes the right choice, then the rewards could be enormous. One penny stock that could be put into the watch list at this point in time is that of CytoDyn Inc (OTCMKTS:CYDY).

The late-stage biotechnology company, which is developing the coronavirus medicine leronlimab, announced last week that it had filed a comprehensive application for uplisting on NASDAQ. The company announced that it believes that its application satisfies the myriad listing requirements of the NASDAQ Capital Market.

The Chief Executive Officer and President of the company Nader Pourhassan stated that while it is true that the entire process is expected to take many weeks, CytoDyn is hopeful of success in this matter.

He went on to state that a listing on NASDAQ will not only provide shareholders with more liquidity but also give CytoDyn much bigger access to fresh capital. It is a significant development for the company, and the market participants realized it as well. After the announcement was made, the stock rallied by as much as 50%. Investors could do well to keep an eye on the stock this week.

While the rally following this announcement was a welcome relief for the company, it is important to point out that earlier on in the week, the stock has fallen considerably following a setback. Last Monday, the company announced that the United States Food and Drug Administration handed CytoDyn a refusal to file a letter with regards to the usage of leronlimab to treat HIV.

However, at the same time, investors should be noted that the company did announce that it is confident of furnishing the agency with all the further details that have been demanded. It is one of the penny stocks that have performed remarkably well this year so far, and investors could keep an eye on it.

Continue Reading

Market

These 3 Pot Stocks Are Up Big Since May: What’s the Buzz?

Published

on

By

Over the course of the past year or so, pot stocks had generally struggled, but during the past month, those stocks have recovered nicely. The stock market suffered a historic fall due to the economic turmoil caused by the coronavirus pandemic. It is believed that investors who are looking for value have descended on the beaten-down pot stocks. On the flip side, these stocks could also have been identified as defensive plays in an uncertain market environment.

That being said, it should be noted that despite the gains recorded by many stocks, most of those stocks are still considerably lower than the all-time highs. In such a situation, it could be worthwhile for investors to take a closer look at some of the strongest and more stable cannabis companies in the industry. Here is a look at three pot stocks that made significant moves in May and could be tracked by investors at this point.

1. HEXO Stock Jumps Ahead of Earnings

HEXO Corp (TSX:HEXO) (NYSE:HEXO) is one of those cannabis companies which have had a particularly tough time over the past year or so. However, the stock has emerged as one of the bigger gainers among pot stocks in recent trading sessions. The Hexo stock has gained as much as 120% over the course of the past month. The company is all set to release its financial results for the fiscal third quarter on Thursday, and hence, it could be a big week for the stock.

The recent surge in the Hexo stock may have come as a major boost to investors, but it should be noted that over the past year, it recorded considerable losses. The beaten-down nature of the stock may have contributed to the stock becoming more attractive for investors. However, the trajectory of the Hexo stock in the near term is going to depend a lot on its third-quarter earnings.

The company had made a loss of $298 million in the previous quarter, and while it is almost certain that it is going to make a loss again, the size of the loss is going to be keenly watched. Additionally, any writedowns are also going to be harmful to the stock. Investors should also keep an eye on sales growth.

2 Organigram gains Momentum on Value Buying

Organigram Holdings (TSX:OGI) (NASDAQ:OGI) is another pot stock that has made significant gains in the past month. Since May 13, the stock has gained as much as 80%. In April, the company announced its fiscal second-quarter results, but it had been a disappointment.

Revenues dropped by 13.7% year on year to hit CA$23.2 million, and losses widened to CA$6.8 million from CA$6.4 million in the prior-year period. However, one significant cause for optimism for Organigram investors is the fact that in the second quarter, cannabis 2.0 products made up as much as 13% of its revenue. That has opened up a whole new opportunity for the company.

Wholesale cannabis revenue made up 24% of the net, and that is again a new source of revenue. The company blamed the lower volumes of flower as well as cannabis oil for the drop in sales. Organigram reported cash and cash equivalents of CA$41.1 million as of February 29. Considering the fact that it has burned CA$25 million in the past six months, investors should not use that the cash balance does not paint a pretty picture.

3 Aphria Recovers Following Solid Earnings

Aphria (TSX:APHA) (NYSE:APHA), on the other hand, managed to perform relatively well in its fiscal third quarter. The net sales rose by as much as 19.7% sequentially to hit CA$144.4 million, and more importantly, the company also managed to record a profit for the third time in four quarters. On top of that, it should be noted that although the Canadian cannabis company spends CA$124.4 million on its operations in the nine months trailing that quarter, it still reported a cash balance of CA$515 million.

The performance seems to have buoyed market participants as well, and the stock has rallied by as much as 75% since the middle of May. One of the most important things that investors are going to be looking into is whether Aphria is going to be able to maintain its profitability.

However, due to the turmoil caused by the coronavirus pandemic, it might prove difficult. That being said, it should be noted that the pandemic is going to have an equally damaging effect across the sector.

Continue Reading

Market

ConforMIS Inc (NASDAQ: CFMS): Premium Members Made A Quick 65% Profit In Just 1 week

Published

on

Well, as we know there are two types of person in the stock market one is trader and another is investor. Investors tend to put money for longer time, while traders make short term bets. We know, its not at all easy to make money in the short term especially in the equity markets. However, premium members at Traders Insights are making awesome money on our calls on our swing trading calls. WE ARE OFFERING A SPECIAL 7-Day Trial Period at Just $5 (so that everybody can make money with us and join us if satisfied). Register Here http://tradersinsights.com/pricing/
JOIN US NOW: For Details Contact us at info@tradersinsights.com

Or You can send me a friend request on facebook here https://www.facebook.com/sebastian.gomestradersinsights

Now let me show you how we made quick 43% in just 1-week which was posted to our premium members:-

We told our members in facebook private group to buy ConforMIS Inc (NASDAQ: CFMS) yesterday (march 13th) at $1.36. Now look at the price of the stock – its up 65% at $2.25 from our buy price. This is how easy money they made. If you had invested $5,000 in CFMS, it could had been moved up to $8,250. It’s not yet late, join us at info@tradersinsights.com

Continue Reading
Advertisement

Trending